Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com

MELBOURNE, Australia, April 3, 2017 /PRNewswire/ -- Propanc Health Group Corporation (OTCQB: PPCH), an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that James Nathanielsz, Chief Executive Officer, will present live at VirtualInvestorConferences.com on April 6, 2017.

DATE: Thursday, April 6, 2017
TIME: 9:15am EDT
LINK: https://tinyurl.com/0406prepr

This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the association's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.

It is recommended that investors pre-register and run the online system check to save time and receive event updates.

Learn more about the event at www.VirtualInvestorConferences.com.

Recent Company Highlights:

• Propanc completed the low dose group for its GLP-Compliant 28-day repeat-dose toxicity study for its lead product, PRP. No treatment related effects were observed in the animals in this study.
• Propanc received a notification of allowance for its lead patent application from the U.S. Patent Office. The patent application provides broad coverage for a method of treating a solid tumor through administering a pharmaceutical composition comprising a therapeutically effective amount of trypsinogen and chymotrypsinogen to patients.

To view Propanc's "Mechanism of Action" video on anti-cancer product candidate, PRP, please click on the following link:  http://www.propanc.com/news-media/video

To be added to Propanc's email distribution list, please email PPCH@kcsa.com with "Propanc" in the subject line.

About Propanc:
Propanc is developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds, which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ pancreatic proenzymes, which are inactive precursors of enzymes. In the near term, we intend to target patients with limited remaining therapeutic options for the treatment of solid tumors. In future, we intend to develop our lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening. For more information, visit: www.propanc.com.

About VirtualInvestorConferences.com
Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/propanc-health-group-corporation-to-webcast-live-at-virtualinvestorconferencescom-april-6-300429532.html

SOURCE Propanc Health Group Corporation